Benzinga | Jan 4, 2021 07:32AM EST

Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder

NEW HAVEN, Conn., Jan. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive disorder (OCD). Biohaven is advancing the 280 mg once daily dose of troriluzole into two double-blind, placebo-controlled Phase 3 clinical trials with identical study designs and plans to enroll approximately 600 patients in each of these adjunctive treatment trials across study sites in both the United States and Europe. A prior proof of concept study with adjunctive troriluzole in patients with OCD showed a clinically meaningful effect at all study timepoints in patients who had an inadequate response to existing standard of care treatment. Although the study sample size in Phase 2 did not demonstrate statistical significance, the data from the previous trial was instrumental in refining and powering the Phase 3 studies.